Skip to main content

REVIEW article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1436581

IMMUNE-MEDIATED INFLAMMATORY DISEASES AND CANCER -A DANGEROUS LIAISON

Provisionally accepted
Jeanette A. Maier Jeanette A. Maier 1*Sara Castiglioni Sara Castiglioni 1Paolo Fiorina Paolo Fiorina 1Alessandra Petrelli Alessandra Petrelli 1Rosanna Cannatelli Rosanna Cannatelli 2Francesca Ferretti Francesca Ferretti 2Greta Pellegrino Greta Pellegrino 3Piercarlo Sarzi Puttini Piercarlo Sarzi Puttini 1,3Sandro Ardizzone Sandro Ardizzone 2
  • 1 University of Milan, Milan, Lombardy, Italy
  • 2 Other, Milan, Italy
  • 3 IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Lombardy, Italy

The final, formatted version of the article will be published soon.

    Patients with Immune-Mediated Inflammatory Diseases (IMIDs) are known to have an elevated risk of developing cancer, but the exact causative factors remain subject to ongoing debate. This narrative review aims to present the available evidence concerning the intricate relationship between these two conditions. Environmental influences and genetic predisposition lead to a dysregulated immune response resulting in chronic inflammation, which is crucial in the pathogenesis of IMIDs and oncogenic processes. Mechanisms such as the inflammatory microenvironment, aberrant intercellular communication due to abnormal cytokine levels, excessive reparative responses, and pathological angiogenesis are involved. The chronic immunosuppression resulting from IMIDs treatments further adds to the complexity of the pathogenic scenario. In conclusion, this review highlights critical gaps in the current literature, suggesting potential avenues for future research. The intricate interplay between IMIDs and cancer necessitates more investigation to deepen our understanding and improve patient management.

    Keywords: immune-mediated inflammatory diseases, Inflammation, Immunosuppression, biologic therapy, malignancy, Immune dysregulation

    Received: 22 May 2024; Accepted: 29 Aug 2024.

    Copyright: © 2024 Maier, Castiglioni, Fiorina, Petrelli, Cannatelli, Ferretti, Pellegrino, Sarzi Puttini and Ardizzone. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jeanette A. Maier, University of Milan, Milan, 20122, Lombardy, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.